The most common histology type was adenocarcinoma in 66.3% vs 60.6%, and 42.5% vs 40.6% had PD-L1 expression of less than 1%. The safety analysis included all patients who had received at least 1 dose of treatment. Any AEs occurred in 93.8% in the durvalumab arm and 92.3% in the ...
despite relatively similar patient demographic and clinical characteristics; however, it should be acknowledged that data pertaining to ECOG performance status, PD-L1 tumor cell expression, and molecular testing (ie, the presence of an EGFR variant), all of which can impact immunotherapy decisions in...
Hierarchical Multiple Testing Procedure eFigure 3. Subgroup Analysis of Overall Survival for Durvalumab Monotherapy Versus Chemotherapy Among Patients With PD-L1 TC ≥25% eFigure 4. TMB Dataset and Blood TMB Correlation With Tissue TMB eFigure 5. Overall Survival in the ITT, Blood and Tissue TMB...
In animal models, inhibition of PD-L1/PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. Mycobacterium tuberculosis-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferat...
批准日期:2017年5月1日公司:阿斯利康公司IMFINZI(durvalumab)注射液,用于静脉注射美国最初批准:2017年最近的重大变警告和注意事项:02/2018作用机制程序性细胞死亡配体-1(PD-L1)的表达可以由炎性信号(例如,IFN-γ)诱导,并且可以在肿瘤微环境中的肿瘤细胞和肿瘤相关免疫细胞上表达。PD-L1通过与PD-1和CD80的相互作用...
The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer...
In my opinion, the much more interesting area will be the neoadjuvant approach to the utilization of PD-1/PD-L1 antibodies. This is particularly interesting because you have a higher tumor mutational burden, so maybe you should introduce a higher immune response prior to taking out the tumor....
PD-L1 was assessed using the SP263 antibody; ≥1% immune and tumor cell staining was considered positive; sTILs were calculated as the area occupied by mononuclear inflammatory cells over the total intratumoral stromal area. 59 patients were evaluable for toxicity and 55 for efficacy in the Phase...
Pretreatment tumor tissue samples were available for 261 patients for central PD-L1 TC testing (87% of those randomized) and bTMB data for 236 patients (78.4% of those randomized). The remaining patients had insufficient tissue samples for submission or PD-L1 scoring or insufficient plasma or ce...
By testing increasingly conservative CTF thresholds, we arrived at CTF = 1.68% as a threshold by which to exclude possible low-shedding samples, as the rate of KRAS wildtype status reached 12.7% at this threshold (Supplementary Fig. 3A). Repeating the survival analysis using only samples ...